Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 70 entries
Sorted by: Best Match Show Resources per page
Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial.

JAMA surgery

van Workum F, Verstegen MHP, Klarenbeek BR, Bouwense SAW, van Berge Henegouwen MI, Daams F, Gisbertz SS, Hannink G, Haveman JW, Heisterkamp J, Jansen W, Kouwenhoven EA, van Lanschot JJB, Nieuwenhuijzen GAP, van der Peet DL, Polat F, Ubels S, Wijnhoven BPL, Rovers MM, Rosman C.
PMID: 33978698
JAMA Surg. 2021 Jul 01;156(7):601-610. doi: 10.1001/jamasurg.2021.1555.

BACKGROUND: Transthoracic minimally invasive esophagectomy (MIE) is increasingly performed as part of curative multimodality treatment. There appears to be no robust evidence on the preferred location of the anastomosis after transthoracic MIE.OBJECTIVE: To compare an intrathoracic with a cervical...

Cite
van Workum F, Verstegen MHP, Klarenbeek BR, et al. Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial. JAMA Surg. 2021;156(7):601-610doi: 10.1001/jamasurg.2021.1555.
van Workum, F., Verstegen, M. H. P., Klarenbeek, B. R., Bouwense, S. A. W., van Berge Henegouwen, M. I., Daams, F., Gisbertz, S. S., Hannink, G., Haveman, J. W., Heisterkamp, J., Jansen, W., Kouwenhoven, E. A., van Lanschot, J. J. B., Nieuwenhuijzen, G. A. P., van der Peet, D. L., Polat, F., Ubels, S., Wijnhoven, B. P. L., Rovers, M. M., Rosman, C. (2021). Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial. JAMA surgery, 156(7), 601-610. https://doi.org/10.1001/jamasurg.2021.1555
van Workum, Frans, et al. "Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial." JAMA surgery vol. 156,7 (2021): 601-610. doi: https://doi.org/10.1001/jamasurg.2021.1555
van Workum F, Verstegen MHP, Klarenbeek BR, Bouwense SAW, van Berge Henegouwen MI, Daams F, Gisbertz SS, Hannink G, Haveman JW, Heisterkamp J, Jansen W, Kouwenhoven EA, van Lanschot JJB, Nieuwenhuijzen GAP, van der Peet DL, Polat F, Ubels S, Wijnhoven BPL, Rovers MM, Rosman C. Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial. JAMA Surg. 2021 Jul 01;156(7):601-610. doi: 10.1001/jamasurg.2021.1555. PMID: 33978698; PMCID: PMC8117060.
Copy Download .nbib Format: NLM
18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC).

JAMA surgery

Gertsen EC, Brenkman HJF, van Hillegersberg R, van Sandick JW, van Berge Henegouwen MI, Gisbertz SS, Luyer MDP, Nieuwenhuijzen GAP, van Lanschot JJB, Lagarde SM, Wijnhoven BPL, de Steur WO, Hartgrink HH, Stoot JHMB, Hulsewe KWE, Spillenaar Bilgen EJ, van Det MJ, Kouwenhoven EA, van der Peet DL, Daams F, van Grieken NCT, Heisterkamp J, van Etten B, van den Berg JW, Pierie JP, Eker HH, Thijssen AY, Belt EJT, van Duijvendijk P, Wassenaar E, van Laarhoven HWM, Wevers KP, Hol L, Wessels FJ, Haj Mohammad N, van der Meulen MP, Frederix GWJ, Vegt E, Siersema PD, Ruurda JP.
PMID: 34705049
JAMA Surg. 2021 Dec 01;156(12):e215340. doi: 10.1001/jamasurg.2021.5340. Epub 2021 Dec 08.

IMPORTANCE: The optimal staging for gastric cancer remains a matter of debate.OBJECTIVE: To evaluate the value of 18F-fludeoxyglucose-positron emission tomography with computed tomography (FDG-PET/CT) and staging laparoscopy (SL) in addition to initial staging by means of gastroscopy and CT...

Cite
Gertsen EC, Brenkman HJF, van Hillegersberg R, et al. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC). JAMA Surg. 2021;156(12):e215340doi: 10.1001/jamasurg.2021.5340.
Gertsen, E. C., Brenkman, H. J. F., van Hillegersberg, R., van Sandick, J. W., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., van Lanschot, J. J. B., Lagarde, S. M., Wijnhoven, B. P. L., de Steur, W. O., Hartgrink, H. H., Stoot, J. H. M. B., Hulsewe, K. W. E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Grieken, N. C. T., Heisterkamp, J., van Etten, B., van den Berg, J. W., Pierie, J. P., Eker, H. H., Thijssen, A. Y., Belt, E. J. T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W. M., Wevers, K. P., Hol, L., Wessels, F. J., Haj Mohammad, N., van der Meulen, M. P., Frederix, G. W. J., Vegt, E., Siersema, P. D., Ruurda, J. P. (2021). 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC). JAMA surgery, 156(12), e215340. https://doi.org/10.1001/jamasurg.2021.5340
Gertsen, Emma C, et al. "18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC)." JAMA surgery vol. 156,12 (2021): e215340. doi: https://doi.org/10.1001/jamasurg.2021.5340
Gertsen EC, Brenkman HJF, van Hillegersberg R, van Sandick JW, van Berge Henegouwen MI, Gisbertz SS, Luyer MDP, Nieuwenhuijzen GAP, van Lanschot JJB, Lagarde SM, Wijnhoven BPL, de Steur WO, Hartgrink HH, Stoot JHMB, Hulsewe KWE, Spillenaar Bilgen EJ, van Det MJ, Kouwenhoven EA, van der Peet DL, Daams F, van Grieken NCT, Heisterkamp J, van Etten B, van den Berg JW, Pierie JP, Eker HH, Thijssen AY, Belt EJT, van Duijvendijk P, Wassenaar E, van Laarhoven HWM, Wevers KP, Hol L, Wessels FJ, Haj Mohammad N, van der Meulen MP, Frederix GWJ, Vegt E, Siersema PD, Ruurda JP. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC). JAMA Surg. 2021 Dec 01;156(12):e215340. doi: 10.1001/jamasurg.2021.5340. Epub 2021 Dec 08. PMID: 34705049; PMCID: PMC8552113.
Copy Download .nbib Format: NLM
Treating Early Delayed Gastric Tube Emptying after Esophagectomy with Pneumatic Pyloric Dilation.

Digestive surgery

Mertens A, Gooszen J, Fockens P, Voermans R, Gisbertz S, Bredenoord A, van Berge Henegouwen MI.
PMID: 34727541
Dig Surg. 2021;38(5):337-342. doi: 10.1159/000519785. Epub 2021 Nov 02.

INTRODUCTION: Endoscopic pneumatic pyloric balloon dilation is a treatment option for early postoperative delayed gastric tube emptying following esophageal resection. This study aimed to determine the safety and effectiveness of endoscopic balloon dilation.METHODS: Between 2015 and 2018, patients with...

Cite
Mertens A, Gooszen J, Fockens P, et al. Treating Early Delayed Gastric Tube Emptying after Esophagectomy with Pneumatic Pyloric Dilation. Dig Surg. 2021;38(5):337-342doi: 10.1159/000519785.
Mertens, A., Gooszen, J., Fockens, P., Voermans, R., Gisbertz, S., Bredenoord, A., & van Berge Henegouwen, M. I. (2021). Treating Early Delayed Gastric Tube Emptying after Esophagectomy with Pneumatic Pyloric Dilation. Digestive surgery, 38(5), 337-342. https://doi.org/10.1159/000519785
Mertens, Alexander, et al. "Treating Early Delayed Gastric Tube Emptying after Esophagectomy with Pneumatic Pyloric Dilation." Digestive surgery vol. 38,5 (2021): 337-342. doi: https://doi.org/10.1159/000519785
Mertens A, Gooszen J, Fockens P, Voermans R, Gisbertz S, Bredenoord A, van Berge Henegouwen MI. Treating Early Delayed Gastric Tube Emptying after Esophagectomy with Pneumatic Pyloric Dilation. Dig Surg. 2021;38(5):337-342. doi: 10.1159/000519785. Epub 2021 Nov 02. PMID: 34727541.
Copy Download .nbib Format: NLM
Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Hagens E, Tukanova K, Jamel S, van Berge Henegouwen M, Hanna GB, Gisbertz S, Markar SR.
PMID: 33893494
Dis Esophagus. 2022 Jan 07;35(1). doi: 10.1093/dote/doab021.

INTRODUCTION: The prognostic value of histomorphologic regression in primary esophageal cancer has been previously established, however the impact of lymph node (LN) response on survival still remains unclear. The aim of this review was to assess the prognostic significance...

Cite
Hagens E, Tukanova K, Jamel S, et al. Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2022;35(1)doi: 10.1093/dote/doab021.
Hagens, E., Tukanova, K., Jamel, S., van Berge Henegouwen, M., Hanna, G. B., Gisbertz, S., & Markar, S. R. (2022). Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 35(1), . https://doi.org/10.1093/dote/doab021
Hagens, Eliza, et al. "Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis." Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus vol. 35,1 (2022). doi: https://doi.org/10.1093/dote/doab021
Hagens E, Tukanova K, Jamel S, van Berge Henegouwen M, Hanna GB, Gisbertz S, Markar SR. Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2022 Jan 07;35(1). doi: 10.1093/dote/doab021. PMID: 33893494.
Copy Download .nbib Format: NLM
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.

Clinical cancer research : an official journal of the American Association for Cancer Research

van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW.
PMID: 34475104
Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 02.

PURPOSE: To assess the efficacy of olaparib, a PARP inhibitor (PARPi) in patients with tumors with PATIENTS AND METHODS: Patients with treatment-refractory RESULTS: Twenty-four evaluable patients with nine different tumor types harboring CONCLUSIONS: These data indicate that using PARPis...

Cite
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, et al. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clin Cancer Res. 2021;27(22):6106-6114doi: 10.1158/1078-0432.CCR-21-1104.
van der Wijngaart, H., Hoes, L. R., van Berge Henegouwen, J. M., van der Velden, D. L., Zeverijn, L. J., Roepman, P., van Werkhoven, E., de Leng, W. W. J., Jansen, A. M. L., Mehra, N., Robbrecht, D. G. J., Labots, M., de Groot, D. J. A., Hoeben, A., Hamberg, P., Gelderblom, H., Voest, E. E., & Verheul, H. M. W. (2021). Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(22), 6106-6114. https://doi.org/10.1158/1078-0432.CCR-21-1104
van der Wijngaart, Hanneke, et al. "Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,22 (2021): 6106-6114. doi: https://doi.org/10.1158/1078-0432.CCR-21-1104
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 02. PMID: 34475104.
Copy Download .nbib Format: NLM
Staging laparoscopy in patients with advanced gastric cancer: A single center cohort study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Borgstein ABJ, Keywani K, Eshuis WJ, van Berge Henegouwen MI, Gisbertz SS.
PMID: 34384656
Eur J Surg Oncol. 2021 Aug 08; doi: 10.1016/j.ejso.2021.08.003. Epub 2021 Aug 08.

BACKGROUND: Most studies exploring the role of staging laparoscopy in gastric cancer are limited by low sample size and are predominantly conducted in Asian countries. This study sets out to determine the value of staging laparoscopy in patients with...

Cite
Borgstein ABJ, Keywani K, Eshuis WJ, et al. Staging laparoscopy in patients with advanced gastric cancer: A single center cohort study. Eur J Surg Oncol. 2021;doi: 10.1016/j.ejso.2021.08.003.
Borgstein, A. B. J., Keywani, K., Eshuis, W. J., van Berge Henegouwen, M. I., & Gisbertz, S. S. (2021). Staging laparoscopy in patients with advanced gastric cancer: A single center cohort study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, . https://doi.org/10.1016/j.ejso.2021.08.003
Borgstein, Alexander B J, et al. "Staging laparoscopy in patients with advanced gastric cancer: A single center cohort study." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology vol. (2021). doi: https://doi.org/10.1016/j.ejso.2021.08.003
Borgstein ABJ, Keywani K, Eshuis WJ, van Berge Henegouwen MI, Gisbertz SS. Staging laparoscopy in patients with advanced gastric cancer: A single center cohort study. Eur J Surg Oncol. 2021 Aug 08; doi: 10.1016/j.ejso.2021.08.003. Epub 2021 Aug 08. PMID: 34384656.
Copy Download .nbib Format: NLM
European consensus on essential steps of Minimally Invasive Ivor Lewis and McKeown Esophagectomy through Delphi methodology.

Surgical endoscopy

Eddahchouri Y, van Workum F, van den Wildenberg FJH, van Berge Henegouwen MI, Polat F, van Goor H, Pierie JEN, Klarenbeek BR, Gisbertz SS, Rosman C.
PMID: 33608767
Surg Endosc. 2022 Jan;36(1):446-460. doi: 10.1007/s00464-021-08304-5. Epub 2021 Feb 19.

BACKGROUND: Minimally invasive esophagectomy (MIE) is a complex and technically demanding procedure with a long learning curve, which is associated with increased morbidity and mortality. To master MIE, training in essential steps is crucial. Yet, no consensus on essential...

Cite
Eddahchouri Y, van Workum F, van den Wildenberg FJH, et al. European consensus on essential steps of Minimally Invasive Ivor Lewis and McKeown Esophagectomy through Delphi methodology. Surg Endosc. 2021;36(1):446-460doi: 10.1007/s00464-021-08304-5.
Eddahchouri, Y., van Workum, F., van den Wildenberg, F. J. H., van Berge Henegouwen, M. I., Polat, F., van Goor, H., Pierie, J. E. N., Klarenbeek, B. R., Gisbertz, S. S., & Rosman, C. (2022). European consensus on essential steps of Minimally Invasive Ivor Lewis and McKeown Esophagectomy through Delphi methodology. Surgical endoscopy, 36(1), 446-460. https://doi.org/10.1007/s00464-021-08304-5
Eddahchouri, Yassin, et al. "European consensus on essential steps of Minimally Invasive Ivor Lewis and McKeown Esophagectomy through Delphi methodology." Surgical endoscopy vol. 36,1 (2022): 446-460. doi: https://doi.org/10.1007/s00464-021-08304-5
Eddahchouri Y, van Workum F, van den Wildenberg FJH, van Berge Henegouwen MI, Polat F, van Goor H, Pierie JEN, Klarenbeek BR, Gisbertz SS, Rosman C. European consensus on essential steps of Minimally Invasive Ivor Lewis and McKeown Esophagectomy through Delphi methodology. Surg Endosc. 2022 Jan;36(1):446-460. doi: 10.1007/s00464-021-08304-5. Epub 2021 Feb 19. PMID: 33608767.
Copy Download .nbib Format: NLM
Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.

The Annals of thoracic surgery

Kroese TE, Dijksterhuis WPM, van Rossum PSN, Verhoeven RHA, Mook S, Haj Mohammad N, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, Ruurda JP, van Laarhoven HWM, van Hillegersberg R.
PMID: 33610543
Ann Thorac Surg. 2022 Feb;113(2):482-490. doi: 10.1016/j.athoracsur.2021.01.061. Epub 2021 Feb 18.

BACKGROUND: In esophageal cancer patients, distant metastases develop between the start of neoadjuvant chemoradiotherapy and planned surgery, so-called interval metastases. The primary aim of this study was to assess management, overall survival (OS), and prognostic factors for OS in...

Cite
Kroese TE, Dijksterhuis WPM, van Rossum PSN, et al. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Ann Thorac Surg. 2021;113(2):482-490doi: 10.1016/j.athoracsur.2021.01.061.
Kroese, T. E., Dijksterhuis, W. P. M., van Rossum, P. S. N., Verhoeven, R. H. A., Mook, S., Haj Mohammad, N., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., van Oijen, M. G. H., Ruurda, J. P., van Laarhoven, H. W. M., & van Hillegersberg, R. (2022). Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. The Annals of thoracic surgery, 113(2), 482-490. https://doi.org/10.1016/j.athoracsur.2021.01.061
Kroese, Tiuri E, et al. "Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer." The Annals of thoracic surgery vol. 113,2 (2022): 482-490. doi: https://doi.org/10.1016/j.athoracsur.2021.01.061
Kroese TE, Dijksterhuis WPM, van Rossum PSN, Verhoeven RHA, Mook S, Haj Mohammad N, Hulshof MCCM, van Berge Henegouwen MI, van Oijen MGH, Ruurda JP, van Laarhoven HWM, van Hillegersberg R. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Ann Thorac Surg. 2022 Feb;113(2):482-490. doi: 10.1016/j.athoracsur.2021.01.061. Epub 2021 Feb 18. PMID: 33610543.
Copy Download .nbib Format: NLM
Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.

Endoscopy

Gotink AW, van de Ven SEM, Ten Kate FJC, Nieboer D, Suzuki L, Weusten BLAM, Brosens LAA, van Hillegersberg R, Alvarez Herrero L, Seldenrijk CA, Alkhalaf A, Moll FCP, Schoon EJ, van Lijnschoten I, Tang TJ, van der Valk H, Nagengast WB, Kats-Ugurlu G, Plukker JTM, Houben MHMG, van der Laan JS, Pouw RE, Bergman JJGHM, Meijer SL, van Berge Henegouwen MI, Wijnhoven BPL, de Jonge PJF, Doukas M, Bruno MJ, Biermann K, Koch AD.
PMID: 33626582
Endoscopy. 2021 Feb 24; doi: 10.1055/a-1399-4989. Epub 2021 Feb 24.

BACKGROUND:  Lymph node metastasis (LNM) is possible after endoscopic resection of early esophageal adenocarcinoma (EAC). This study aimed to develop and internally validate a prediction model that estimates the individual risk of metastases in patients with pT1b EAC.METHODS:  A...

Cite
Gotink AW, van de Ven SEM, Ten Kate FJC, et al. Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Endoscopy. 2021;doi: 10.1055/a-1399-4989.
Gotink, A. W., van de Ven, S. E. M., Ten Kate, F. J. C., Nieboer, D., Suzuki, L., Weusten, B. L. A. M., Brosens, L. A. A., van Hillegersberg, R., Alvarez Herrero, L., Seldenrijk, C. A., Alkhalaf, A., Moll, F. C. P., Schoon, E. J., van Lijnschoten, I., Tang, T. J., van der Valk, H., Nagengast, W. B., Kats-Ugurlu, G., Plukker, J. T. M., Houben, M. H. M. G., van der Laan, J. S., Pouw, R. E., Bergman, J. J. G. H. M., Meijer, S. L., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., de Jonge, P. J. F., Doukas, M., Bruno, M. J., Biermann, K., & Koch, A. D. (2021). Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Endoscopy, . https://doi.org/10.1055/a-1399-4989
Gotink, Annieke W, et al. "Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study." Endoscopy vol. (2021). doi: https://doi.org/10.1055/a-1399-4989
Gotink AW, van de Ven SEM, Ten Kate FJC, Nieboer D, Suzuki L, Weusten BLAM, Brosens LAA, van Hillegersberg R, Alvarez Herrero L, Seldenrijk CA, Alkhalaf A, Moll FCP, Schoon EJ, van Lijnschoten I, Tang TJ, van der Valk H, Nagengast WB, Kats-Ugurlu G, Plukker JTM, Houben MHMG, van der Laan JS, Pouw RE, Bergman JJGHM, Meijer SL, van Berge Henegouwen MI, Wijnhoven BPL, de Jonge PJF, Doukas M, Bruno MJ, Biermann K, Koch AD. Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Endoscopy. 2021 Feb 24; doi: 10.1055/a-1399-4989. Epub 2021 Feb 24. PMID: 33626582.
Copy Download .nbib Format: NLM
Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma.

United European gastroenterology journal

van de Ven SEM, Suzuki L, Gotink AW, Ten Kate FJC, Nieboer D, Weusten BLAM, Brosens LAA, van Hillegersberg R, Alvarez Herrero L, Seldenrijk CA, Alkhalaf A, Moll FCP, Curvers W, van Lijnschoten IG, Tang TJ, van der Valk H, Nagengast WB, Kats-Ugurlu G, Plukker JTM, Houben MHMG, van der Laan JS, Pouw RE, Bergman JJGHM, Meijer SL, van Berge Henegouwen MI, Wijnhoven BPL, de Jonge PJF, Doukas M, Bruno MJ, Biermann K, Koch AD.
PMID: 34609076
United European Gastroenterol J. 2021 Nov;9(9):1066-1073. doi: 10.1002/ueg2.12151. Epub 2021 Oct 05.

AIM: To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma.METHODS: In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal...

Cite
van de Ven SEM, Suzuki L, Gotink AW, et al. Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma. United European Gastroenterol J. 2021;9(9):1066-1073doi: 10.1002/ueg2.12151.
van de Ven, S. E. M., Suzuki, L., Gotink, A. W., Ten Kate, F. J. C., Nieboer, D., Weusten, B. L. A. M., Brosens, L. A. A., van Hillegersberg, R., Alvarez Herrero, L., Seldenrijk, C. A., Alkhalaf, A., Moll, F. C. P., Curvers, W., van Lijnschoten, I. G., Tang, T. J., van der Valk, H., Nagengast, W. B., Kats-Ugurlu, G., Plukker, J. T. M., Houben, M. H. M. G., van der Laan, J. S., Pouw, R. E., Bergman, J. J. G. H. M., Meijer, S. L., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., de Jonge, P. J. F., Doukas, M., Bruno, M. J., Biermann, K., & Koch, A. D. (2021). Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma. United European gastroenterology journal, 9(9), 1066-1073. https://doi.org/10.1002/ueg2.12151
van de Ven, Steffi E M, et al. "Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma." United European gastroenterology journal vol. 9,9 (2021): 1066-1073. doi: https://doi.org/10.1002/ueg2.12151
van de Ven SEM, Suzuki L, Gotink AW, Ten Kate FJC, Nieboer D, Weusten BLAM, Brosens LAA, van Hillegersberg R, Alvarez Herrero L, Seldenrijk CA, Alkhalaf A, Moll FCP, Curvers W, van Lijnschoten IG, Tang TJ, van der Valk H, Nagengast WB, Kats-Ugurlu G, Plukker JTM, Houben MHMG, van der Laan JS, Pouw RE, Bergman JJGHM, Meijer SL, van Berge Henegouwen MI, Wijnhoven BPL, de Jonge PJF, Doukas M, Bruno MJ, Biermann K, Koch AD. Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma. United European Gastroenterol J. 2021 Nov;9(9):1066-1073. doi: 10.1002/ueg2.12151. Epub 2021 Oct 05. PMID: 34609076; PMCID: PMC8598963.
Copy Download .nbib Format: NLM
Long-Term Survival After Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Propensity-Score Matched Analysis.

Annals of surgery

Kalff MC, Fransen LFC, de Groot EM, Gisbertz SS, Nieuwenhuijzen GAP, Ruurda JP, Verhoeven RHA, Luyer MDP, van Hillegersberg R, van Berge Henegouwen MI.
PMID: 33378310
Ann Surg. 2020 Dec 23; doi: 10.1097/SLA.0000000000004708. Epub 2020 Dec 23.

OBJECTIVES: This study aimed to compare long-term survival following minimally invasive esophagectomy (MIE) versus open esophagectomy (OE) for esophageal cancer using a nationwide propensity-score matched cohort.SUMMARY BACKGROUND DATA: MIE provides lower postoperative morbidity and mortality, and similar short-term oncological...

Cite
Kalff MC, Fransen LFC, de Groot EM, et al. Long-Term Survival After Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Propensity-Score Matched Analysis. Ann Surg. 2020;doi: 10.1097/SLA.0000000000004708.
Kalff, M. C., Fransen, L. F. C., de Groot, E. M., Gisbertz, S. S., Nieuwenhuijzen, G. A. P., Ruurda, J. P., Verhoeven, R. H. A., Luyer, M. D. P., van Hillegersberg, R., van Berge Henegouwen, M. I. (2020). Long-Term Survival After Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Propensity-Score Matched Analysis. Annals of surgery, . https://doi.org/10.1097/SLA.0000000000004708
Kalff, Marianne C, et al. "Long-Term Survival After Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Propensity-Score Matched Analysis." Annals of surgery vol. (2020). doi: https://doi.org/10.1097/SLA.0000000000004708
Kalff MC, Fransen LFC, de Groot EM, Gisbertz SS, Nieuwenhuijzen GAP, Ruurda JP, Verhoeven RHA, Luyer MDP, van Hillegersberg R, van Berge Henegouwen MI. Long-Term Survival After Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Propensity-Score Matched Analysis. Ann Surg. 2020 Dec 23; doi: 10.1097/SLA.0000000000004708. Epub 2020 Dec 23. PMID: 33378310.
Copy Download .nbib Format: NLM
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Kalff MC, Wagner AD, Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz SS, van Berge Henegouwen MI.
PMID: 34365540
Gastric Cancer. 2022 Jan;25(1):22-32. doi: 10.1007/s10120-021-01225-1. Epub 2021 Aug 07.

BACKGROUND: Sex differences in clinicopathological characteristics, treatment, and postoperative outcomes of gastric and esophageal cancer are largely undefined. This study aimed to compare tumor and treatment characteristics and outcomes of gastric and esophageal cancer surgery between male and female...

Cite
Kalff MC, Wagner AD, Verhoeven RHA, et al. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer. 2021;25(1):22-32doi: 10.1007/s10120-021-01225-1.
Kalff, M. C., Wagner, A. D., Verhoeven, R. H. A., Lemmens, V. E. P. P., van Laarhoven, H. W. M., Gisbertz, S. S., van Berge Henegouwen, M. I. (2022). Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25(1), 22-32. https://doi.org/10.1007/s10120-021-01225-1
Kalff, Marianne C, et al. "Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit." Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association vol. 25,1 (2022): 22-32. doi: https://doi.org/10.1007/s10120-021-01225-1
Kalff MC, Wagner AD, Verhoeven RHA, Lemmens VEPP, van Laarhoven HWM, Gisbertz SS, van Berge Henegouwen MI. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer. 2022 Jan;25(1):22-32. doi: 10.1007/s10120-021-01225-1. Epub 2021 Aug 07. PMID: 34365540.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 70 entries